TickerFacts.

TriSalus Life Sciences, Inc. (TLSI): Cost of Revenue

Annual figures by period end, from SEC filings.

$6.96M
Year ended 2025-12-31
$6.41M
Trailing 12 months to 2026-06-30
+45.6%
3-year compound annual growth
2022-12-31: $2.26M2023-12-31: $2.60M2024-12-31: $4.10M2025-12-31: $6.96M$6.96M
2022-12-31 Cost of Revenue (USD) 2025-12-31
Period endedCost of RevenueChange YoYSource filing
2025-12-31$6.96M+69.8%2026-03-05, From 2025-01-01
2024-12-31$4.10M+57.5%2026-03-05, From 2024-01-01
2023-12-31$2.60M+15.4%2025-05-30, From 2023-01-01
2022-12-31$2.26Mn/a2024-04-11, From 2022-01-01

Cost of Revenue at similar companies

Companies with the same SEC industry code (Surgical & Medical Instruments & Apparatus), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedCost of RevenueChange YoY
TriSalus Life Sciences, Inc. (TLSI)2025-12-31$6.96M+69.8%
SANUWAVE Health, Inc. (SNWV)2025-12-31$10.08M+24.7%
Shoulder Innovations, Inc. (SI)2025-12-31$11.12M+52.6%
SS Innovations International, Inc. (SSII)2025-12-31$22.94M+88.1%
KORU Medical Systems, Inc. (KRMD)2025-12-31$15.52M+26.1%
Carlsmed, Inc. (CARL)2025-12-31$12.47M+75.2%
Interpace Biosciences, Inc. (IDXG)2025-12-31$14.60M-14.1%
Apyx Medical Corp (APYX)2025-12-31$19.80M+5.6%
Utah Medical Products Inc (UTMD)2025-12-31$16.52M-1.4%

Compare TLSI, SNWV, SI, SSII side by side · Screen every company in Surgical & Medical Instruments & Apparatus ↗